Amneal resubmits dhe autoinjector new drug application and receives u.s. fda approval of exenatide, its first generic injectable glp-1 agonist

Bridgewater, n.j.--(business wire)--amneal resubmits dhe autoinjector new drug application and receives u.s. fda approval of exenatide, its first generic injectable glp-1 agonist.
AMRX Ratings Summary
AMRX Quant Ranking